Bioceltix obtains permit to manufacture veterinary medicines
18:03
Bioceltix has received approval from the Chief Pharmaceutical Inspector (GIF) to modify its veterinary medicine license. This change allows the company to produce and sell veterinary medicinal products, a shift from its previous role of producing only for research. The company views this as a significant milestone in advancing its product commercialization. Bioceltix, a biotechnology firm focusing on therapeutic products for companion animals like dogs and horses, went public on the NewConnect market in November 2021 and on the main GPW market in September 2022.
